Methylation markers for diagnosis and treatment of ovarian cancer
View Patent ↗Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.
1. A method for identifying an ovarian cell as neoplastic, comprising:
detecting in a test ovarian cell epigenetic silencing of a gene encoding TM4SF11 transmembrane 4 superfamily member 11 (plasmolipin); and identifying the test ovarian cell as neoplastic when epigentic silencing of transmembrane 4 superfamily member 11 (plasmolipin) is detected.
2. The method of claim 1 further comprising detecting in the test ovarian cell epigenetic silencing of at least one gene encoding a protein selected from the group consisting of: TNFRSF10B tumor necrosis factor receptor superfamily (member 10b), RUNX3 runt-related transcription factor 3, ACTN1 actinin (alpha 1), and FANCG Fanconi anemia (complementation group G).
3. The method of claim 1 wherein methylation of a CpG dinucleotide motif in the gene is detected.
4. The method of claim 3 wherein methylation is detected by contacting at least a portion of the gene with a methylation-sensitive restriction endonuclease, said endonuclease preferentially cleaving methylated recognition sites relative to non-methylated recognition sites, whereby cleavage of the portion of the gene indicates methylation of the portion of the gene.
5. The method of claim 4 wherein the methylation-sensitive restriction endonuclease is selected from the group consisting of Acc III, Ban I, BstN I, Msp I, and Xma I.
6. The method of claim 5 wherein methylation is detected by contacting at least a portion of the gene with a methylation-sensitive restriction endonuclease, said endonuclease preferentially cleaving non-methylated recognition sites relative to methylated recognition sites, whereby cleavage of the portion of the gene indicates non-methylation of the portion of the gene provided that the gene comprises a recognition site for the methylation-sensitive restriction endonuclease.
7. The method of claim 6 wherein the methylation-sensitive restriction endonuclease is selected from the group consisting of Acc II, Ava I, BssH II, BstU I, Hpa II, and Not I.
8. The method of claim 3 wherein methylation is detected by:
contacting at least a portion of the gene of the test cell with bisulfite ions, which selectively modify a non-methylated cytosine residue relative to a methylated cytosine residue, or with hydrazine, which selectively modifies a methylated cytosine residue relative to a non-methylated cytosine residue; and
detecting a product generated due to said contacting.
9. The method of claim 8 wherein the step of detecting comprises amplification with at least one primer that hybridizes to a sequence comprising a modified non-methylated CpG dinucleotide motif but not to a sequence comprising an unmodified methylated CpG dinucleotide motif thereby forming amplification products.
10. The method of claim 8 wherein the step of detecting comprises amplification with at least one primer that hybridizes to a sequence comprising an unmodified methylated CpG dinucleotide motif but not to a sequence comprising a modified non-methylated CpG dinucleotide motif thereby forming amplification products.
11. The method of claim 9 wherein the amplification products are detected using (a) a first oligonucleotide probe which hybridizes to a sequence comprising a modified non-methylated CpG dinucleotide motif but not to a sequence comprising an unmodified methylated CpG dinucleotide motif, (b) a second oligonucleotide probe that hybridizes to a sequence comprising an unmodified methylated CpG dinucleotide motif but not to sequence comprising a modified non-methylated CpG dinucleotide motif, or (c) both said first and second oligonucleotide probes.
12. The method of claim 10 wherein the amplification products are detected using (a) a first oligonucleotide probe which hybridizes to a sequence comprising a modified non-methylated CpG dinucleotide motif but not to a sequence comprising an unmodified methylated CpG dinucleotide motif, (b) a second oligonucleotide probe that hybridizes to a sequence comprising an unmodified methylated CpG dinucleotide motif but not to sequence comprising a modified non-methylated CpG dinucleotide motif, or (c) both said first and second oligonucleotide probes.
13. The method of claim 8 wherein the product is detected by a method selected from the group consisting of electrophoresis, chromatography, and mass spectrometry.
14. The method of claim 8 wherein the at least a portion of the gene is contacted with hydrazine and the hydrazine-contacted at least a portion of the gene is cleaved with piperidine.
15. The method of claim 8 wherein the at least a portion of the gene is contacted with bisulfite ions and the bisulfite ions-contacted at least a portion of the gene is treated with alkali.
16. The method of claim 3 wherein methylation is detected by:
amplifying at least a portion of the gene, said portion comprising a CpG dinucleotide motif, to form amplification products;
contacting the amplification products with bisulfite ions, which selectively modify a non-methylated cytosine residue relative to a methylated cytosine residue, or with hydrazine, which selectively modifies a methylated cytosine residue relative to a non-methylated cytosine residue; and
detecting a product generated due to said contacting using (a) a first oligonucleotide probe which hybridizes to a sequence comprising a modified non-methylated CpG dinucleotide motif but not to a sequence comprising an unmodified methylated CpG dinucleotide motif, (b) a second oligonucleotide probe that hybridizes to a sequence comprising an unmodified methylated CpG dinucleotide motif but not to sequence comprising a modified non-methylated CpG dinucleotide motif, or (c) both said first and second oligonucleotide probes.
17. The method of claim 1 wherein the test ovarian cell is obtained from a surgical sample.